US Stock MarketDetailed Quotes
CVKD Cadrenal Therapeutics
- 14.280
- -3.320-18.86%
Close Nov 4 16:00 ET
- 14.280
- 0.0000.00%
Post 20:01 ET
21.37MMarket Cap-2441P/E (TTM)
17.800High14.000Low152.18KVolume17.730Open17.600Pre Close2.31MTurnover16.33%Turnover RatioLossP/E (Static)1.50MShares32.55052wk High5.35P/B13.31MFloat Cap5.40052wk Low--Dividend TTM931.79KShs Float101.250Historical High--Div YieldTTM21.59%Amplitude5.400Historical Low15.196Avg Price1Lot Size
Cadrenal Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||
| Cash flow from continuing operating activities | -92.28%-1.53M | -29.98%-1.84M | -3.53M | -694.45K | -627.78K | -795.31K | -3,133.01%-1.41M | -43.7K |
| Net income from continuing operations | -138.58%-2.39M | 67.85%-1.66M | ---8.36M | ---1.14M | ---1.04M | ---1M | -2,828.75%-5.17M | ---176.65K |
| Operating gains losses | ---- | ---- | --956.23K | --0 | --0 | --0 | 62,073.86%956.23K | --1.54K |
| Depreciation and amortization | -21.14%470 | 214.21%597 | --1.98K | --597 | --597 | --596 | --190 | --0 |
| Other non cash items | -216.48%-106 | -100.00%-105 | --3.01M | --24 | --89 | --91 | 120,061.68%3.01M | --2.51K |
| Change In working capital | 1,609.53%670.25K | 32.15%-336.32K | --144.31K | --345.88K | --254.92K | --39.21K | -484.55%-495.7K | --128.9K |
| -Change in prepaid assets | -12.78%58.82K | 27.09%-204.09K | ---66.96K | --78.93K | --66.59K | --67.44K | -12,588.67%-279.91K | ---2.21K |
| -Change in payables and accrued expense | 2,278.52%614.97K | 104.00%35.62K | ---463.22K | --266.95K | --188.33K | ---28.23K | -773.40%-890.27K | --132.21K |
| -Change in other current assets | --0 | --0 | --2.2K | ---1 | --1 | ---1 | 300.18%2.2K | ---1.1K |
| -Change in other working capital | ---3.54K | -124.97%-167.84K | --672.3K | --0 | --0 | --0 | --672.3K | ---- |
| Cash from discontinued investing activities | ||||||||
| Operating cash flow | -92.28%-1.53M | -29.98%-1.84M | ---3.53M | ---694.45K | ---627.78K | ---795.31K | -3,133.01%-1.41M | ---43.7K |
| Investing cash flow | ||||||||
| Cash flow from continuing investing activities | -3.25K | 0 | -1 | |||||
| Net PPE purchase and sale | ---- | ---- | ---3.25K | --0 | ---1 | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||
| Investing cash flow | ---- | ---- | ---3.25K | --0 | ---1 | ---- | ---- | ---- |
| Financing cash flow | ||||||||
| Cash flow from continuing financing activities | 0 | -99.99%298 | 11.9M | -12.5K | 6.51M | 0 | 968.80%5.41M | 506.04K |
| Net issuance payments of debt | --0 | --0 | ---250K | --0 | --0 | --0 | -150.15%-250K | --498.54K |
| Net common stock issuance | --0 | --0 | --11.9M | ---12.5K | --6.51M | --0 | 72,014.33%5.41M | --7.5K |
| Proceeds from stock option exercised by employees | --0 | -99.88%298 | --250K | --0 | --0 | --0 | --250K | ---- |
| Cash from discontinued financing activities | ||||||||
| Financing cash flow | --0 | -99.99%298 | --11.9M | ---12.5K | --6.51M | --0 | 968.80%5.41M | --506.04K |
| Net cash flow | ||||||||
| Beginning cash position | 63.00%6.57M | 25,685.61%8.4M | --32.59K | --9.11M | --3.23M | --4.03M | --32.59K | --0 |
| Current changes in cash | -91.50%-1.53M | -145.95%-1.84M | --8.37M | ---706.95K | --5.88M | ---798.56K | 764.25%4M | --462.34K |
| End cash Position | 55.96%5.04M | 63.00%6.57M | --8.4M | --8.4M | --9.11M | --3.23M | 771.30%4.03M | --462.34K |
| Free cash flow | -91.50%-1.53M | -29.98%-1.84M | ---3.53M | ---694.45K | ---627.78K | ---798.56K | -3,133.01%-1.41M | ---43.7K |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data